The new clinical guideline recommends statin therapy to prevent atherosclerotic cardiovascular disease (ASCVD) in adults with HIV, based on the findings from the REPRIEVE trial. The guideline emphasizes the benefits of pitavastatin in reducing major cardiovascular events, particularly in patients with a 10-year ASCVD risk of at least 5%. It also highlights the importance of careful statin selection due to potential interactions with antiretroviral medications and the need for clinician-patient discussions in low-risk cases.

Source: Annals of Internal Medicine